REGN — Regeneron Pharmaceuticals
Data coverage, completeness and provenance for Regeneron Pharmaceuticals in the Stock Market API — Health Care · Biotechnology.
Stored price coverage
Source date: 2026-11-19T21:00:00. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 923.3400 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 945.5300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 957.7600 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 952.4000 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 955.4700 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/REGN/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Employees: 15,410 · Website: https://www.regeneron.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/REGN/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 28 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 28 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 28 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 27 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 28 | sec_edgar |
Get REGN data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/REGN
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/REGN/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/REGN/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/REGN/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/REGN
Query REGN programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for REGN?
- Stored coverage for REGN: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/REGN; inspect available source metadata for provenance.
- How complete is REGN's financial data?
- The anchor reporting period (FY2025) has 88.2% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for REGN?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/REGN/financials.
- Where does REGN's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/REGN/financials; missing tags do not establish provenance.